The Top 5 Biosimilar Articles for the Week of March 25

Number 5: A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.

Number 4: Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.

Number 3: Senators Michael Bennet (D-Colorado) and John Cornyn (R-Texas) have reintroduced the Increasing Access to Biosimilars Act to Congress. The bill’s aim is to boost competition and increase incentives for providers to prescribe biosimilars over their more expensive reference agents.

Number 2: Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.

Number 1: Sandoz revenues increased 7% overall last year, including a 15% spike in biosimilar sales, according to the company’s earnings report for the fourth quarter (Q4) and full year (FY) 2023.

To read all of these articles and more, visit centerforbiosimilars.com.